Robert O. Dillman - Concepedia

Author

Robert O. Dillman

Hoag Memorial Hospital Presbyterian ORCID

Also Known As

Jacquelyn Beauregard Dillman, R O DILLMAN, R O Dillman, R. Dillman, R. O. DILLMAN, R. O. Dillman, R.O. DILLMAN, R.O. Dillman, ROBERT O. DILLMAN, Robert Dillman

323

Publications

8.1K

Citations

H-Index

128

Concepts

All Affiliations

Hoag Memorial Hospital Presbyterian University of California San Diego

About

Robert O. Dillman is an author at Hoag Memorial Hospital Presbyterian specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	59	2.4K
2	Health Sciences	11	13	829
3	Engineering	2	2	50
4	Natural Sciences	1	1	11
5	Nursing	1	1	20

Robert O. Dillman

105

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer Robert O. Dillman, Stephen L. Seagren, Kathleen J. Propert, New England Journal of Medicine	1990	1.2K
Human immune response to multiple injections of murine monoclonal IgG. Daniel L. Shawler, Richard M. Bartholomew, Leia M. Smith, The Journal of Immunology	1985	426
Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger, Journal of Clinical Oncology	2006	358
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab Thomas A. Davis, Christine A. White, A.J. Grillo-López, Journal of Clinical Oncology ImmunologyImmunotherapyHematological MalignancyOncologyHematology	1999	289
Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. Robert O. Dillman, Daniel L. Shawler, Jacquelyn B. Dillman, Journal of Clinical Oncology Chronic Lymphocytic LeukemiaImmunologyPathologyImmunophenotypingImmunotherapy	1984	175
Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. Robert O. Dillman, Rosemarie Mick, O. Ross McIntyre Journal of Clinical Oncology Chronic Lymphocytic LeukemiaPathologyPharmacotherapyMyeloid NeoplasiaHematological Malignancy	1989	144
Tumor size: effect on monoclonal antibody uptake in tumor models. Phillip L. Hagan, Samuel E. Halpern, Robert O. Dillman, PubMed ImmunologyPathologyImmunotherapyTumor BiologyOncology	1986	134
Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. Robert O. Dillman, R. K. Oldham, Kurt W. Tauer, Journal of Clinical Oncology Cell TherapyImmunologyMetronomic ChemotherapyImmunotherapyNatural Killer Cells	1991	120
Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma Robert O. Dillman, Christopher Duma, Patric M. Schiltz, Journal of Immunotherapy	2004	117
Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial Robert O. Dillman, Neil M. Barth, Robert K. Oldham, Cancer	1991	114

Page 1